83 related articles for article (PubMed ID: 28822152)
21. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
[TBL] [Abstract][Full Text] [Related]
22. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
23. [A study on the cell differentiation induced by tanshinone IIA and its molecular mechanism in retinoic acid: resistant acute promyelocytic leukemia].
Liang Y; Song WX; Wang J; Jing LP; Qu W; Fu R; Wu XZ
Zhonghua Nei Ke Za Zhi; 2005 May; 44(5):366-9. PubMed ID: 16009009
[TBL] [Abstract][Full Text] [Related]
24. Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy.
Wu H; Yao L; Mei J; Li F
Int J Clin Exp Pathol; 2015; 8(1):207-16. PubMed ID: 25755707
[TBL] [Abstract][Full Text] [Related]
25. TPGS-g-PLGA/Pluronic F68 mixed micelles for tanshinone IIA delivery in cancer therapy.
Zhang J; Li Y; Fang X; Zhou D; Wang Y; Chen M
Int J Pharm; 2014 Dec; 476(1-2):185-98. PubMed ID: 25223472
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice.
Lee EM; Yee D; Busfield SJ; McManus JF; Cummings N; Vairo G; Wei A; Ramshaw HS; Powell JA; Lopez AF; Lewis ID; McCall MN; Lock RB
Haematologica; 2015 Jul; 100(7):914-26. PubMed ID: 26130514
[TBL] [Abstract][Full Text] [Related]
27. [Preparation of cell penetrating peptide TAT and cleavable PEGco-modified liposomes loaded with paclitaxel and its in vitro apoptosis assay].
Fu H; Hu GL; He Q
Yao Xue Xue Bao; 2014 Jul; 49(7):1054-61. PubMed ID: 25233640
[TBL] [Abstract][Full Text] [Related]
28. CD123 redirected multiple virus-specific T cells for acute myeloid leukemia.
Zhou L; Liu X; Wang X; Sun Z; Song XT
Leuk Res; 2016 Feb; 41():76-84. PubMed ID: 26740053
[TBL] [Abstract][Full Text] [Related]
29. Combination of doxorubicin with harmine-loaded liposomes exerting synergistic antitumor efficacy.
Lei J; Cong S; Song M; Zhang W; Peng G; Li X; Liu Y
Drug Dev Ind Pharm; 2018 Apr; 44(4):570-581. PubMed ID: 29260918
[TBL] [Abstract][Full Text] [Related]
30. Soluble Expression and Characterization of a New scFv Directed to Human CD123.
Moradi-Kalbolandi S; Davani D; Golkar M; Habibi-Anbouhi M; Abolhassani M; Shokrgozar MA
Appl Biochem Biotechnol; 2016 Apr; 178(7):1390-406. PubMed ID: 26749295
[TBL] [Abstract][Full Text] [Related]
31. An aptamer ligand based liposomal nanocarrier system that targets tumor endothelial cells.
Ara MN; Matsuda T; Hyodo M; Sakurai Y; Hatakeyama H; Ohga N; Hida K; Harashima H
Biomaterials; 2014 Aug; 35(25):7110-20. PubMed ID: 24875764
[TBL] [Abstract][Full Text] [Related]
32. [Preparation and evaluation of RGD and TAT co-modified paclitaxel loaded liposome].
Gao B; Mu W
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Aug; 39(8):769-74. PubMed ID: 25202944
[TBL] [Abstract][Full Text] [Related]
33. [In vitro targeting effect of lactoferrin modified PEGylated liposomes for hepatoma cells].
Wei MY; Zou Q; Wu CB; Xu YH
Yao Xue Xue Bao; 2015 Oct; 50(10):1272-9. PubMed ID: 26837173
[TBL] [Abstract][Full Text] [Related]
34. Cationic liposome (DC-Chol/DOPE=1:2) and a modified ethanol injection method to prepare liposomes, increased gene expression.
Maitani Y; Igarashi S; Sato M; Hattori Y
Int J Pharm; 2007 Sep; 342(1-2):33-9. PubMed ID: 17566677
[TBL] [Abstract][Full Text] [Related]
35. Anti-neuropilin 1 antibody Fab' fragment conjugated liposomal docetaxel for active targeting of tumours.
Manjappa AS; Goel PN; Gude RP; Ramachandra Murthy RS
J Drug Target; 2014 Sep; 22(8):698-711. PubMed ID: 24766186
[TBL] [Abstract][Full Text] [Related]
36. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
37. In vitro anti-tumor activity of the tanshinone IIA against SKOV3 cells.
Huang J; Lin H; Hong Y
Nat Prod Res; 2016 Aug; 30(16):1844-6. PubMed ID: 26252372
[TBL] [Abstract][Full Text] [Related]
38. Microfluidic synthesis of multifunctional liposomes for tumour targeting.
Ran R; Middelberg APJ; Zhao CX
Colloids Surf B Biointerfaces; 2016 Dec; 148():402-410. PubMed ID: 27639490
[TBL] [Abstract][Full Text] [Related]
39. The effect of PEG coating on in vitro cytotoxicity and in vivo disposition of topotecan loaded liposomes in rats.
Dadashzadeh S; Vali AM; Rezaie M
Int J Pharm; 2008 Apr; 353(1-2):251-9. PubMed ID: 18191511
[TBL] [Abstract][Full Text] [Related]
40. Osteopontin plays a unique role in resistance of CD34+/CD123+ human leukemia cell lines KG1a to parthenolide.
Mohammadi S; Zahedpanah M; Ghaffari SH; Shaiegan M; Nikbakht M; Nikugoftar M
Life Sci; 2017 Nov; 189():89-95. PubMed ID: 28935249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
